Ancora Advisors’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $41.1K | Buy |
224
+100
| +81% | +$18.4K | ﹤0.01% | 1230 |
|
|
2025
Q4 | $21.8K | Buy |
124
+122
| +6,100% | +$19.9K | ﹤0.01% | 1517 |
|
|
2025
Q3 | $280 | Hold |
2
| – | – | ﹤0.01% | 1878 |
|
|
2025
Q2 | $251 | Buy |
+2
| New | +$249 | ﹤0.01% | 1884 |
|
|
2025
Q1 | – | Sell |
-2
| Closed | -$306 | – | 1785 |
|
|
2024
Q4 | $306 | Sell |
2
-24
| -92% | -$4.05K | ﹤0.01% | 1707 |
|
|
2024
Q3 | $5.04K | Sell |
26
-19
| -42% | -$3.98K | ﹤0.01% | 1446 |
|
|
2024
Q2 | $10.4K | Sell |
45
-35
| -44% | -$7.61K | ﹤0.01% | 1293 |
|
|
2024
Q1 | $17.3K | Sell |
80
-161
| -67% | -$37.7K | ﹤0.01% | 1222 |
|
|
2023
Q4 | $62.4K | Hold |
241
| – | – | ﹤0.01% | 889 |
|
|
2023
Q3 | $61.9K | Hold |
241
| – | – | ﹤0.01% | 868 |
|
|
2023
Q2 | $68.6K | Hold |
241
| – | – | ﹤0.01% | 842 |
|
|
2023
Q1 | $67K | Buy |
241
+25
| +12% | +$6.92K | ﹤0.01% | 847 |
|
|
2022
Q4 | $60K | Sell |
216
-25
| -10% | -$7.06K | ﹤0.01% | 926 |
|
|
2022
Q3 | $64K | Sell |
241
-150
| -38% | -$31.9K | ﹤0.01% | 1011 |
|
|
2022
Q2 | $80K | Hold |
391
| – | – | ﹤0.01% | 1029 |
|
|
2022
Q1 | $82K | Sell |
391
-114
| -23% | -$24.8K | ﹤0.01% | 1089 |
|
|
2021
Q4 | $121K | Sell |
505
-868
| -63% | -$223K | ﹤0.01% | 967 |
|
|
2021
Q3 | $389K | Buy |
1,373
+25
| +2% | +$8.19K | 0.01% | 607 |
|
|
2021
Q2 | $467K | Hold |
1,348
| – | – | 0.01% | 559 |
|
|
2021
Q1 | $377K | Sell |
1,348
-25
| -2% | -$6.74K | 0.01% | 584 |
|
|
2020
Q4 | $336K | Sell |
1,373
-45
| -3% | -$11.6K | 0.01% | 537 |
|
|
2020
Q3 | $402K | Sell |
1,418
-500
| -26% | -$139K | 0.02% | 476 |
|
|
2020
Q2 | $513K | Sell |
1,918
-2,923
| -60% | -$879K | 0.02% | 421 |
|
|
2020
Q1 | $1.53M | Sell |
4,841
-1,193
| -20% | -$362K | 0.07% | 255 |
|
|
2019
Q4 | $1.79M | Buy |
6,034
+38
| +0.6% | +$10.5K | 0.07% | 266 |
|
|
2019
Q3 | $1.4M | Buy |
5,996
+1,100
| +22% | +$256K | 0.06% | 274 |
|
|
2019
Q2 | $1.15M | Sell |
4,896
-575
| -11% | -$133K | 0.05% | 265 |
|
|
2019
Q1 | $1.29M | Sell |
5,471
-25
| -0.5% | -$7.87K | 0.06% | 270 |
|
|
2018
Q4 | $1.65M | Buy |
5,496
+125
| +2% | +$39.9K | 0.08% | 232 |
|
|
2018
Q3 | $1.9M | Sell |
5,371
-119
| -2% | -$41K | 0.07% | 243 |
|
|
2018
Q2 | $1.59M | Sell |
5,490
-1,160
| -17% | -$326K | 0.07% | 260 |
|
|
2018
Q1 | $1.82M | Buy |
6,650
+415
| +7% | +$129K | 0.08% | 243 |
|
|
2017
Q4 | $1.99M | Buy |
6,235
+324
| +5% | +$104K | 0.11% | 210 |
|
|
2017
Q3 | $1.85M | Buy |
5,911
+106
| +2% | +$31.4K | 0.11% | 222 |
|
|
2017
Q2 | $1.57M | Buy |
5,805
+93
| +2% | +$24.6K | 0.1% | 235 |
|
|
2017
Q1 | $1.56M | Buy |
5,712
+17
| +0.3% | +$4.81K | 0.11% | 230 |
|
|
2016
Q4 | $1.61M | Buy |
+5,695
| New | +$1.69M | 0.12% | 215 |
|
Other funds holding BIIB
VCM
VPM
Ancora Advisors's BIIB Position: Q1 2026 in Review
Ancora Advisors increased its Biogen (BIIB) stake by 81% in Q1 2026, buying an estimated $18.4K and bringing the position to 224 shares worth $41.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1230.
Ancora Advisors first reported a position in BIIB in Q4 2016 and has held it in 37 quarters since. The position peaked at $1.99M in Q4 2017. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Ancora Advisors held 224 shares of Biogen worth $41.1K as of Q1 2026.
- Ancora Advisors bought 100 Biogen shares in Q1 2026, an estimated $18.4K.
- Biogen made up ﹤0.01% of Ancora Advisors's portfolio in Q1 2026, its #1230 holding.
- Ancora Advisors first reported a position in Biogen in Q4 2016 and has held it in 37 quarters since.
- Ancora Advisors's Biogen position peaked at $1.99M in Q4 2017.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Ancora Advisors's 13F filing for Q1 2026, filed 15 May 2026.